REAL LIFE. REAL RESULTS.

 
People need to understand that schizoaffective disorder isn’t hopeless.
Katie, being treated with INVEGA® SUSTENNA® for schizoaffective disorder.

Schizoaffective Disorder

After 15 Months, 85% of Patients on
INVEGA® SUSTENNA® Remained Relapse-Free1

 

INVEGA® SUSTENNA® helped more patients remain
relapse-free vs placebo, both as1:

  • Monotherapy—88% vs 67%
  • Adjunctive therapy *—81% vs 66%

*Adjunct to antidepressants or mood stabilizers.

The full constellation of symptoms and the relevant diagnostic criteria should be consulted and are available in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5 or current version), where applicable.

INVEGA® SUSTENNA® (paliperidone palmitate) is approved for the treatment of schizoaffective disorder.
 
 

Patients Treated With INVEGA® SUSTENNA® Who Did Not Relapse Due to Psychotic or Mood Symptoms Over 15 Months1

 

Of the 82 patients who relapsed on INVEGA® SUSTENNA® (n=25) and placebo (n=57), the majority of patients experienced symptoms of both psychosis and mood at the time of their relapse. Only 8 of the 82 patients experienced a relapse without psychotic symptoms and 16 of the 82 patients experienced a relapse without mood symptoms.1

The full constellation of symptoms and the relevant diagnostic criteria should be consulted and are available in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5 or current version), where applicable.

INVEGA® SUSTENNA® (paliperidone palmitate) is approved for the treatment of schizoaffective disorder.
 
 

Most Common Adverse Reactions1

  • In the 5 pivotal trials for INVEGA® SUSTENNA® in patients with schizophrenia, the most common adverse reactions (incidence ≥5% and occurring at least twice as often as placebo) were1:
    • – injection site reactions
    • – somnolence/sedation
    • – dizziness
    • – akathisia
    • – extrapyramidal disorder
  • No occurrences of adverse events reached this threshold in the 15-month, double-blind, placebo-controlled phase in patients with schizoaffective disorder1
  • The following adverse reactions occurred more frequently (a ≥2% difference vs placebo) in the long-term study in patients with schizoaffective disorder: weight increased, nasopharyngitis, headache, hyperprolactinemia, and pyrexia1
 

References: 1. INVEGA® SUSTENNA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; February 2017. 2. Fu DJ, Turkoz I, Simonson RB, et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. J Clin Psychiatry. 2015;76(3):252-262.